An interventional study of CYOA booklet in Dementia (Diagnosis), Mild Cognitive Impairment and Alzheimer's Disease Dementia, sponsored by The Cleveland Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Supportive care
The purpose of this study is to see if an educational interactive booklet about how dementia progresses throughout a person's life can be a helpful tool for patients to think about future decisions that might need to be made regarding their medical care and helping patients discuss their diagnosis and possible future medical decisions with their family or future caregivers.
Exclusion Criteria:
Other: CYOA booklet
The purpose of the educational booklet in a CYOA format booklet is to provide educational information about the progression of dementia and to help patients to think about potential future medical decisions that may need to be made for them. By being more informed, patients can discuss their wishes with their family members or future caregivers, include preferences in advanced directives, and/or have a discussion with their medical provider about their future care preferences.
The Dementia Knowledge Assessment Tool (DKAT2)
Dementia knowledge will be assessed using the 21-item Dementia Knowledge Assessment Tool Version 2 (DKAT2), which was developed to assess foundation-level knowledge of dementia. Each item has three response options: Yes, No, and Don't Know. Each correct response is assigned 1 point, while an incorrect or Don't Know response is assigned 0 points. Total scores range from 0 to 21, with higher scores indicating greater dementia knowledge. The baseline and follow up assessment may be completed either independently using a paper questionnaire or as an interviewer-administered questionnaire by study personnel. The change in total DKAT2 score from baseline to post-intervention will be assessed.
Time frame: Participants will complete the DKAT2 at baseline, and 1-30 days after reviewing the toolkit at follow-up telephone encounter. The follow-up assessment window may extend 30 additional days if participants wish to remain in the study.
Patient Education Materials Assessment Tool (PEMAT)
Patient Education Materials Assessment Tool (PEMAT), will be used to assess understandability and actionability of print educational material. The PEMAT provides two domain scores: understandability and actionability. Understandability is assessed using 17 items, and actionability is assessed using 7 items. Each applicable item is scored as 1 (agree) or 0 (disagree). Domain scores are calculated as the percentage of applicable items receiving a score of 1. Scores range from 0% to 100% for each domain, with higher scores indicating greater understandability and actionability. Understandability and actionability scores will be reported separately. The PEMAT may be completed as an interviewer-administered questionnaire by study personnel.
Time frame: PEMAT will be completed 1-30 days after reviewing the toolkit at follow-up telephone encounter along with DKAT2. The follow-up assessment window may extend 30 additional days if participants wish to remain in the study.
Participant-Reported Educational Material Evaluation and Engagement
There are four open ended questions that will be evaluated to determine thoughts on the toolkit's strengths and areas for improvement. 1. What are the strengths of this educational material? 2. How much of the booklet did you read? 3. Did you find the booklet helpful? (Agree/disagree) 4. What areas about Alzheimer's dementia did you learn about in the educational booklet to foster conversations? These questions will be completed as an interviewer-administered questionnaire by study personnel.
Time frame: These four questions will be completed 1-30 days after reviewing the toolkit at follow-up telephone encounter along with DKAT2 and PEMAT. The follow-up assessment window may extend 30 additional days if participants wish to remain in the study.
Plan to share: No — De-identified data may be shared on a case-by-case basis after compliance and regulatory approval have been obtained. Access will be provided on a case-by-case basis pending approval by the Cleveland Clinic IRB and law department.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Cleveland Clinic